Redeye ceases its coverage of Lipum and will not provide research on the company following the compl...
* Clear initiatives for efficiency gains presented * Focus on add-on sales and M&A to re-accelerate ...
Waystream has received its first-ever order from Telia Sweden (SEK3m), marking an important mileston...
Last evening, Insplorion communicated a higher bid for its core business from Consilium, totaling ap...
Redeye comments on the recent share price development in Sivers, following elevated trading activity...
Redeye comments on Better Collective’s announcement of expansion into prediction markets with the la...
Redeye comments on Avensia’s preliminary sales figures for February 2026.
* A directed share issue adds MSEK 4.2 before costs * First patient enrolment expected as next trigg...
Xplora completed a NOK150m private placement at NOK52 per share — a reasonable 6.
Redeye comments on AlzeCure Pharma presenting new preclinical data for NeuroRestore ACD856 at the AD...
CapMan continues its strategic execution towards EUR 10bn in AUM by launching Infrastructure debt op...
Redeye is encouraged by FluoGuide receiving FDA Fast Track Designation for FG001 in High-Grade Gliom...
Redeye comments on Isofol’s expansion of its arfolitixorin license to include autism spectrum disord...
Redeye is positive to AAC’s press release today, which states an expected order value of more than E...
Redeye comments on Scandinavian Chemotech announcing that its subsidiary Scandinavian Meditech has r...
Lower volumes mask an improved earnings profile, as Alcadon benefits from exiting its loss-making Ge...
We hosted an investor event with Gofore management that focused on how AI is changing the IT service...
Redeye comments on Sprint Bioscience's announcement of positive preclinical proof-of-concept data fo...
Redeye returns with an update following SciBase Holding’s Q4 report.
* 300k phones sold annually with +30% GM * Same playbook as Doro: add subscriptions * Price not disc...
